Inverse correlation between varicella severity and level of anti-varicella zoster virus maternal antibodies in infants below one year of age

Human Vaccines

Volumn 7, Issue 5, 2011, Pages 534-538

  Pinquier, Didier ^a,b,c,d   Lécuyer, Aurélie ^c,d   Levy, Corinne ^c,d   Gagneur, Arnaud ^e   Pradat, Pierre ^f,g,h   Soubeyrand, Benoît ⁱ   Grimprel, Emmanuel ^c,d  

^a HÔPITAL CHARLES NICOLLE   (France)

^b UNIVERSITÉ DE ROUEN   (France)

^c ACTIV Association Clinique et Thérapeutique Infantile du Val de Marne   (France)

^d Groupe de Pathologie Infectieuse Pediatrique de la Societe Francaise de Pediatrie (GPIP)   (France)

^e CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^f CROIX ROUSSE HOSPITAL   (France)

^g UNIVERSITÉ LYON 1   (France)

^h INSERM   (France)

ⁱ SANOFI PASTEUR   (France)

Author keywords

Complications; Maternal antibodies; Varicella

Indexed keywords

HERPES ZOSTER IMMUNOGLOBULIN; MATERNAL ANTIBODY;

AGE DISTRIBUTION; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; COHORT ANALYSIS; CORRELATIONAL STUDY; DATA ANALYSIS; DISEASE PREDISPOSITION; DISEASE SEVERITY; DISEASE SURVEILLANCE; EMERGENCY WARD; FEMALE; HERPES ZOSTER; HOSPITALIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MOTHER CHILD RELATION; PEDIATRIC WARD; PREVALENCE; PROSPECTIVE STUDY; RISK REDUCTION; SEROPREVALENCE;

ANTIBODIES, VIRAL; CHICKENPOX; FEMALE; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNITY, MATERNALLY-ACQUIRED; INFANT; INFANT, NEWBORN; MALE;

EID: 79955953701     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.5.14820     Document Type: Article

References (28)

1. Galil K, Brown C, Lin F, Seward J. Hospitalizations for varicella in the United States, 1988 to 1999. Pediatr Infect Dis J 2002; 21:931-5.
2. Meyer PA, Seward JF, Jumaan AO, Wharton M. Varicella mortality: trends before vaccine licensure in the United States 1970-1994. J Infect Dis 2000; 182:383-90.
3. Bonmarin I, Ndiaye B, Seringe E, Levy-Bruhl D. Épidé miologie de la varicelle en France. Bull Epidemiol Hebdo 2005; 8:30-1.
4. 2010 vaccination schedule and recommendations from the "Haut Conseil de Santé Publique" in France. Bull Epidemiol Hebdo 2010; 15:131.
5. Lecuyer A, Levy C, Gaudelus J, Floret D, Soubeyrand B, Caulin E, et al. Hospitalization of newborns and young infants for chickenpox in France. Eur J Pediatr 2010; 169:1293-7.
6. van Der Zwet WC, Vandenbroucke-Grauls CM, van Elburg RM, Cranendonk A, Zaaijer HL. Neonatal antibody titers against varicella-zoster virus in relation to gestational age, birth weight and maternal titer. Pediatrics 2002; 109:79-85. (Pubitemid 34049430)
7. Pinquier D, Gagneur A, Balu L, Brissaud O, Gras Le Guen C, Hau-Rainsard I, et al. Prevalence of anti-varicella-zoster virus antibodies in French infants under 15 months of age. Clin Vaccine Immunol 2009; 16:484-7.
8. Lecuyer A, Levy C, Gaudelus J, Soubeyrand B, Caulin E, Grimprel E. Hospitalization for varicella before 3 months of age in France. Arch Pediatr 2009; 16:924-5.
9. Khoshnood B, Debruyne M, Lancon F, Emery C, Fagnani F, Durand I, et al. Seroprevalence of varicella in the French population. Pediatr Infect Dis J 2006; 25:41-4. (Pubitemid 43361474)
10. Saadatian-Elahi M, Mekki Y, Del Signore C, Lina B, Derrough T, Caulin E, et al. Seroprevalence of varicella antibodies among pregnant women in Lyon-France. Eur J Epidemiol 2007; 22:405-9. (Pubitemid 47052083)
11. Junker AK, Tilley P. Varicella-zoster virus antibody avidity and IgG-subclass patterns in children with recurrent chickenpox. J Med Virol 1994; 43:119-24. (Pubitemid 24236650)
12. Bendig JW, Meurisse EV, Anderson F, Diaz H, Shankar A. Neonatal varicella despite maternal immunity. Lancet 1998; 352:1985-6. (Pubitemid 29000870)
13. Koehring J, Frosch M, Bramswig JH. Varicella zoster infection and IgG antibody formation in a 10-week-old preterm infant despite maternal immunity. Eur J Pediatr 2001; 160:684-5. (Pubitemid 33030302)
14. Bazin H. L'histoire des vaccinations.ed.: John Libbey 2008; 112-3.
15. Forthergill LD, Wright J. Influenza meningitis: the relation of age incidence to the bactericidal power of blood against the causal organism. J Immunol 1933; 24:273-84.
16. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969; 129:1307-26.
17. Lin FY, Weisman LE, Azimi PH, Philips JB, 3rd, Clark P, Regan J, et al. Level of maternal IgG anti-group B streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen. J Infect Dis 2004; 190:928-34. (Pubitemid 39120970)
18. Anderson RM, May RM, Anderson B. Infectious Diseases of Humans: Dynamics and Control ed.: Oxford University Press USA 1992; 77.
19. Yeager AS, Arvin AM. Reasons for the absence of a history of recurrent genital infections in mothers of neonates infected with herpes simplex virus. Pediatrics 1984; 73:188-93. (Pubitemid 14188502)
20. Yeager AS, Arvin AM, Urbani LJ, Kemp JA, 3rd. Relationship of antibody to outcome in neonatal herpes simplex virus infections. Infect Immun 1980; 29:532-8.
21. Leuridan E, Hens N, Hutse V, Aerts M, Van Damme P. Kinetics of maternal antibodies against rubella and varicella in infants. Vaccine 2011; 29: 2222-6.
22. Varicella-Zoster infections Red Book Online.ed.: American Academy of Pediatrics. http://aapredbook.aappublications.org/cgi/content/full/2009/1/3.150 2009; 714-27 (visited November 2010).
23. Goh P, Lim FS, Han HH, Willems P. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age. Infection 2007; 35:326-33. (Pubitemid 47502355)
24. th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). Nice, France, May 4-8, 2010.
25. th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). Nice, France, May 4-8, 2010.
26. Grimprel E, Levy C, de La Rocque F, Cohen R, Soubeyrand B, Caulin E, et al. Paediatric varicella hospitalisations in France: a nationwide survey. Clin Microbiol Infect 2007; 13:546-9. (Pubitemid 46563508)
27. Chris Maple PA, Gray J, Brown K, Brown D. Performance characteristics of a quantitative, standardised varicella zoster IgG time resolved fluorescence immunoassay (VZV TRFIA) for measuring antibody following natural infection. J Virol Methods 2009; 157:90-2.
28. Maple PAC, Gray J, Breuer J, Kafatos G, Parker S, Brown D. Performance of a time-resolved fluorescence immunoassay for measuring varicella-zoster virus immunoglobulin G levels in adults and comparison with commercial enzyme immunoassays and Merck glycoprotein enzyme immunoassay. Clin Vaccine Immunol 2006; 13:214-8. (Pubitemid 43383789)